• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
169717 161 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  5 W# p. x# @( q6 U# I- M+ I  H. L

7 S* ?7 B; U0 t3 m: Y6 x6 g1 ]8 ~9 \& b" Q" l" f" x
Sub-category:/ D7 K4 d2 S8 n) w7 j! d
Molecular Targets   y+ C' R  M1 a+ V3 s' `  M" W1 ]
2 _4 C* s9 d' }0 D4 L& q

7 e  ]" {9 O! i9 MCategory:
- S" j! Q' G$ n# ]/ k  l$ v8 ~Tumor Biology
( {# _: _- Q4 d# B( ^! q: M" |1 z6 q8 c9 n, d4 w
( U3 S1 |( \  d$ A, [  t
Meeting:2 b+ B' T( J& c: c! U+ v
2011 ASCO Annual Meeting 6 o: m1 ?: Z& R7 N# N( y/ d

/ z" V% y! ]3 d  e, X3 M/ {; Y" s; w" @7 n
Session Type and Session Title:( l6 m) O$ ?1 c; y+ }" S
Poster Discussion Session, Tumor Biology , Y8 X' a9 o" z' d

9 j3 [3 G' ~; ?9 P1 E0 p" _
$ ]) [/ u/ H) vAbstract No:
  m5 N+ P  n8 ^0 e. R2 Y10517 ! Y. s" V. w( T: \

8 H: x/ ^' X7 e6 X) A1 V
3 `4 O8 `8 b" W# dCitation:
) t. P% i6 e7 h, J* r1 \$ t: kJ Clin Oncol 29: 2011 (suppl; abstr 10517)
" z$ G9 `6 P% L/ R( H9 N
  s( P: q0 u- J* M* _
8 Y* d4 _' e0 m7 t: v$ FAuthor(s):
7 e& [" O8 Y. f: \* L) U! LJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China , B& |$ X; y0 G0 W9 Z

, C/ t) `3 a6 n, b3 \1 X5 N2 |( ]+ o. {7 t
& q: `8 [% ^. i" ?! V9 {
Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.% _4 d- J) B0 J2 G, Q1 c
) \4 f7 k. u3 U$ N) M  m7 ^! P
Abstract Disclosures( O0 [, y3 A& [( j" @
) A; W* F7 i5 {1 @  }
Abstract:$ Z7 h3 b" R0 U- n1 t8 [
. R  t! A8 I$ M* y) n/ s6 l( a
; T' }/ M$ h6 B; T6 Z  G) g
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
! I  F' B5 u7 C$ g  \( E6 s+ Q3 |, c+ @. K; }
! j$ U0 W, v' X9 d
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 , S0 s8 j6 y. Y$ r9 ?5 {
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?

0 y% g: a# r8 A4 d( H化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20 - Y: z( M0 _+ j& ]0 d2 a7 k
易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。
. V- Q, {) l: w, f: U2 ?ALK一个指标医院要900多 ...
+ J) Q  K& u0 V  }
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
- @  D! l: _. ~. {- n* P9 Y& l: s  f9 ?4 @9 k2 w+ m  T
现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表